《公司業績》嘉和生物-B(06998.HK)半年虧損收窄至4.01億人民幣
嘉和生物-B(06998.HK)公布截至今年6月底止中期業績,虧損收窄至4.01億元人民幣(下同),上年同期蝕5.33億元;每股虧損0.82元。不派息。
以非標準會計準則計算,經調整虧損為2.94億元,而去年同期為2.27億元。
研發開支為2.72億元,而去年同期為3.5億元,主要來自新藥測試費及正在進行的臨床試驗開支及的員工薪金及相關福利成本。
至6月底,內部商業化團隊已為即將推出GB226新產品作好充分的準備及培訓。與合同銷售組織在非核心市場推廣、第三方物流及分銷商公司方面已建立穩固的合夥關係。已開始上市前的營銷活動,如參與多個國家及地區的血液學及淋巴瘤相關會議,分享GB226在r/r PTCL研究的強大數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.